$TEM News

What Happens To Tempus AI Stock If Its Cash Burn Continues?

Tempus Receives IVDR Certification for xR RNA Sequencing for Solid Tumor Profiling

How Tempus AI Built A Defensible Data Moat In Precision Healthcare

Tempus AI Gains 6% as Bristol Myers Squibb Licenses Oncology Data

Needham Reiterates Buy on Tempus AI, Maintains $75 Price Target

Tempus Expands Strategic Collaboration with Bristol Myers Squibb

Tempus AI Enters Multiyear Agreement With Bristol Myers Squibb For BMY To License Multimodal Oncology Data Through 2031 To Support Biological And Clinical Insight Identification, Novel Drug Target Discovery And Therapeutic Development Across Its Oncology Portfolio

Tempus Presents Data Demonstrating AI-Enabled Pre-Screening Can Help Identify Patients for Biomarker Testing in NSCLC

Tempus AI To Present Results From Study Evaluating AI-Enabled Pre-Screening Panel For Patients With Advanced Non-Small Cell Lung Cancer, At ESMO Congress 2026

Tempus AI Stock Is The Expanded Drug Collaboration Material To The Bull Case

Tempus to Report Third Quarter 2026 Financial Results on November 2

Ambry Genetics Announces GenomeNext™, a Whole Genome Sequencing Test Solution to Improve Diagnosis for Rare Diseases

Canaccord Genuity Maintains Buy on Tempus AI, Raises Price Target to $95

Tempus AI (TEM) Shares Just Moved, So What Is Going On?

Tempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026

Guggenheim Maintains Buy on Tempus AI, Raises Price Target to $92

Tempus Receives FDA Clearance for its ECG-MR AI Product Designed to Identify Undiagnosed Mitral Regurgitation

Tempus AI Receives 510(k) Clearance From FDA For Tempus ECG-MR, AI Product That Analyzes Standard 12-Lead Resting Ecgs To Detect Signs Associated With Undiagnosed Mitral Regurgitation

Tempus AI Chief Accounting Officer Sells $529,650 of Stock

Tempus AI: High Risk, But With A Great Cause